Enanta Pharmaceuticals, Inc.
Cash Flow Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||
| Net Income | $17.7M | $21.7M | $79.0M | $34.4M | $9.6M | $21.4M | $23.3M |
| Depreciation & Amortization | $2.1M | $1.7M | $639.0K | $352.0K | $221.0K | $172.0K | $499.0K |
| Depreciation | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — |
| Stock-Based Compensation | $13.1M | $9.4M | $5.8M | $2.7M | $1.1M | $424.0K | $225.0K |
| Net Cash from Operating Activities | $52.7M | $35.8M | $76.7M | $20.2M | $10.7M | $22.6M | $24.0M |
| Investing Activities | |||||||
| Capital Expenditures | $2.5M | $4.7M | $2.3M | $1.0M | $606.0K | $252.0K | $445.0K |
| Business Acquisitions | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-4.6M | $-43.7M | — | — | $-69.2M | $-18.0M | $-17.7M |
| Financing Activities | |||||||
| Dividends Paid | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $1.0M | $2.7M | — | — | $56.9M | $-909.0K | $34.0K |
| Net Change in Cash | $49.1M | $-5.1M | $-9.0M | $21.8M | $-1.7M | $3.7M | $6.4M |
| Free Cash Flow | $50.1M | $31.1M | $74.3M | $19.2M | $10.0M | $22.4M | $23.6M |